At the 1st Immunotherapy of Cancer Conference ( ITOC ) at a sponsored symposium supported by BMS Professor Ascierto highlights that I-O therapies, based on immune checkpoint inhibition, are in clinical development. These agents are being investigated for their potential to provide long-term survival in patients with various solid or haematologic malignancies.  Professor Ascierto gives an overview of the clinical experience to date and provides an update on biomarker development.

To view the slides fullscreen click the square and arrows button at the bottom right of the player.